Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

147593

registered interest
date	10/11/2014
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Migrant Workers: Vacancies
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, if she will review the 2011 Migration Advisory Committee's salary recommendations for overhead line workers on the shortage occupation list for inconsistencies in the salary requirements; and if she will make a statement.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	213993
answer	answer is ministerial correction date of answer 17/11/2014 answer text <p>The appropriate salary requirements for Tier 2 workers are determined by the Home Office and are benchmarked against prevailing earnings for individual occupations, drawing on available sources of earnings data including the Annual Survey of Hours and Earnings. While the minimum salary requirement for overhead lines workers fell from £12.33 to £10.12 per hour between 2011 and 2012, the most recent changes to the Shortage Occupation List, effective from 6 April 2014, increased the annual earnings requirement for this occupation from £22,800 to £23,600 for experienced workers, and from £18,100 to £18,600 for new entrants. The Migration Advisory Committee has been asked by the Government to <br>consider the continued inclusion of overhead lines workers on the Shortage Occupation List, and issued a call for evidence on 29 September 2014.</p><p> </p><p> </p><p> </p> answering member constituency Old Bexley and Sidcup answering member printed James Brokenshire grouped question UIN 213992 question first answered 17/11/2014 10:12:18 answering member 1530 label Biography information for James Brokenshire
tabling member	1538 label Biography information for Rosie Cooper

147600

registered interest
date	10/11/2014
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Migrant Workers: Vacancies
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, for what reasons the minimum payment for overhead line workers on the shortage occupation list has been decreased in each subsequent review since November 2011.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	213992
answer	answer is ministerial correction date of answer 17/11/2014 answer text <p>The appropriate salary requirements for Tier 2 workers are determined by the Home Office and are benchmarked against prevailing earnings for individual occupations, drawing on available sources of earnings data including the Annual Survey of Hours and Earnings. While the minimum salary requirement for overhead lines workers fell from £12.33 to £10.12 per hour between 2011 and 2012, the most recent changes to the Shortage Occupation List, effective from 6 April 2014, increased the annual earnings requirement for this occupation from £22,800 to £23,600 for experienced workers, and from £18,100 to £18,600 for new entrants. The Migration Advisory Committee has been asked by the Government to <br>consider the continued inclusion of overhead lines workers on the Shortage Occupation List, and issued a call for evidence on 29 September 2014.</p><p> </p><p> </p><p> </p> answering member constituency Old Bexley and Sidcup answering member printed James Brokenshire grouped question UIN 213993 question first answered 17/11/2014 10:12:18 answering member 1530 label Biography information for James Brokenshire
tabling member	1538 label Biography information for Rosie Cooper

101555

registered interest
date	29/10/2014
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Members: Correspondence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign and Commonwealth Affairs, what the reasons were for the time taken by his Department to reply to correspondence from the hon. Member for West Lancashire on Virunaga National Park.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212379
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>I understand that the unacceptably long delay in providing a response to the correspondence in question was caused by administrative difficulties in transferring the response between Government Departments. The Foreign and Commonwealth Office (FCO) responded to 95 per cent of all ministerial correspondence within its twenty-day deadline in 2013 and I am sorry that, in this instance, the response was not received as promptly as it should have been. The letter from the hon. Member for West Lancashire was recieved by the FCO on 8 September and a response was sent to her on 30 September.</p> answering member constituency Aylesbury answering member printed Mr David Lidington question first answered 03/11/2014 16:18:04 answering member 15 label Biography information for Sir David Lidington
tabling member	1538 label Biography information for Rosie Cooper

101563

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Scotland
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effectiveness and merits of (a) the recently announced New Medicines Fund in Scotland and (b) other funding models aimed at driving improved patient access to innovative medicines in the context of the payments made by the pharmaceutical industry under the current Pharmaceutical Pricing Regulation Scheme.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212458
answer	answer is ministerial correction date of answer 05/11/2014 answer text <p>The New Medicines Fund in Scotland is a matter for the Scottish Government and it would not be appropriate for the Government to comment on its effectiveness or merits.</p><p> </p><p> </p><p> </p><p>In England, in accordance with normal government accounting rules and the agreed 2014 Pharmaceutical Price Regulation Scheme (PPRS), there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients’ health and care. As part of this, NHS England and the Association of the British Pharmaceutical Industry are pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/11/2014 15:04:30 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101565

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure that payments made by the pharmaceutical industry under the current Pharmaceutical Price Regulation Scheme are used to NHS England to achieve measurable and improved access to new medicines by NHS patients.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212418
answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) supports the National Health Service to improve patient access to clinically and cost effective medicines in a number of ways:</p><p> </p><p> </p><p> </p><p>- by making medicines more affordable. The PPRS limits growth in the vast majority of spend on branded medicines with industry making payments for spend above the agreed limit;</p><p> </p><p> </p><p> </p><p>- by providing stability and predictability to the Government and the pharmaceutical industry thereby promoting a strong and profitable pharmaceutical industry which encourages innovation and the development of high value treatments; and</p><p> </p><p> </p><p> </p><p>- by a number of agreed measure to improve access to branded medicines commensurate with the outcomes they offer patients.</p><p> </p><p> </p><p> </p><p>Sales of new products are exempt from PPRS payments though still included in the overall limit on growth and the payments made by industry as a whole. This creates a strong in-built incentive in the scheme for companies to innovate.</p><p> </p><p><br> In respect of England, the anticipated PPRS payments for 2014-15 were passed on to NHS England through the Mandate and as such were included within commissioner allocations. In addition, an indicative budget for NHS England for 2015-16 was set on the basis of, amongst other things, the PPRS payment forecast available in 2014. <br> <br> In accordance with normal Government accounting rules and the agreed PPRS, there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients’ health and care. As part of this, following discussion with the Department, NHS England and the Association of the British Pharmaceutical Industry are now pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.</p><p> </p><p> </p><p> </p><p>More generally, the Government’s <em>Strategy for UK Life Sciences</em> sets out an ambitious long-term programme of action to improve the wider environment for pharmaceutical innovation and make the United Kingdom a world-leading place for life sciences investment. The Strategy has delivered £2 billion in industry and private sector investment in the United Kingdom since it was launched in December 2011.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212417 212419 question first answered 04/11/2014 17:36:41 answering member 4020 label Biography information for George Freeman previous answer version 25830 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101571

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Radiology: Training
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many radiologists are due to finish their training in the next 12 months.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212380
answer	answer is ministerial correction date of answer 05/11/2014 answer text <p>The number of radiologists due to finish their training in the next 12 months in England is in the following table. This table provided by Health Education England uses 2013 data and indicates for every quarter how many trainees are due to complete the programme.</p><p> </p><p> </p><p> </p><p>The 2014 dataset update is due at the end of November. This will include data from more recent annual reviews of competence progression.</p><p> </p><table><tbody><tr><td><p> </p><table><tbody><tr><td><p>Programme Specialty</p></td><td><p>Estimated Finish Date Quarter</p></td><td><p>Estimated Finish Date Year</p></td><td><p>Number of doctors gaining Certificate of Completion of Training</p></td></tr><tr><td><p>Clinical Radiology</p></td><td><p>4</p></td><td><p>2014</p></td><td><p>9</p></td></tr><tr><td><p>Clinical Radiology</p></td><td><p>1</p></td><td><p>2015</p></td><td><p>13</p></td></tr><tr><td><p>Clinical Radiology</p></td><td><p>2</p></td><td><p>2015</p></td><td><p>11</p></td></tr><tr><td><p>Clinical Radiology</p></td><td><p>3</p></td><td><p>2015</p></td><td><p>163</p></td></tr><tr><td><p>Clinical Radiology</p></td><td><p>4</p></td><td><p>2015</p></td><td><p>29</p></td></tr><tr><td><p> </p></td><td><p> </p></td><td><p>Total</p></td><td><p>225</p></td></tr></tbody></table></td></tr></tbody></table><p> </p><p><em>Source: </em>Health Education England</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 05/11/2014 15:00:44 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	1538 label Biography information for Rosie Cooper

101572

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS Trusts: Pay
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many increases to the annual salaries of Chairs of NHS Trusts that were over the limit set by him have been authorised by the NHS Trust Development Authority in each of the last three years.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212381
answer	answer is ministerial correction date of answer 05/11/2014 answer text <p>On 1 October 2012, the Secretary of State for Health transferred responsibility for issues relating to the appointment of chairs of NHS trusts from the Appointments Commission to the NHS Trust Development Authority. Power to determine levels of remuneration payable to them has, however, never been delegated and still rests with the Secretary of State.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 05/11/2014 15:06:06 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	1538 label Biography information for Rosie Cooper

101575

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions (a) he and (b) officials in his Department have had on ensuring that the payments made by the pharmaceutical industry under the current Pharmaceutical Price Regulation Scheme will be used to improve access to innovative medicines.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212417
answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) supports the National Health Service to improve patient access to clinically and cost effective medicines in a number of ways:</p><p> </p><p> </p><p> </p><p>- by making medicines more affordable. The PPRS limits growth in the vast majority of spend on branded medicines with industry making payments for spend above the agreed limit;</p><p> </p><p> </p><p> </p><p>- by providing stability and predictability to the Government and the pharmaceutical industry thereby promoting a strong and profitable pharmaceutical industry which encourages innovation and the development of high value treatments; and</p><p> </p><p> </p><p> </p><p>- by a number of agreed measure to improve access to branded medicines commensurate with the outcomes they offer patients.</p><p> </p><p> </p><p> </p><p>Sales of new products are exempt from PPRS payments though still included in the overall limit on growth and the payments made by industry as a whole. This creates a strong in-built incentive in the scheme for companies to innovate.</p><p> </p><p><br> In respect of England, the anticipated PPRS payments for 2014-15 were passed on to NHS England through the Mandate and as such were included within commissioner allocations. In addition, an indicative budget for NHS England for 2015-16 was set on the basis of, amongst other things, the PPRS payment forecast available in 2014. <br> <br> In accordance with normal Government accounting rules and the agreed PPRS, there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients’ health and care. As part of this, following discussion with the Department, NHS England and the Association of the British Pharmaceutical Industry are now pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.</p><p> </p><p> </p><p> </p><p>More generally, the Government’s <em>Strategy for UK Life Sciences</em> sets out an ambitious long-term programme of action to improve the wider environment for pharmaceutical innovation and make the United Kingdom a world-leading place for life sciences investment. The Strategy has delivered £2 billion in industry and private sector investment in the United Kingdom since it was launched in December 2011.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212418 212419 question first answered 04/11/2014 17:36:41 answering member 4020 label Biography information for George Freeman previous answer version 25828 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101579

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he plans to take to ensure that the payments made by the pharmaceutical industry under the Pharmaceutical Price Regulation Scheme will be apportioned to each of the devolved health administrations, whilst securing that the mechanism in place for determining apportionment ensures that patients in all four constituent parts of the UK receive benefits from the payments made throughout the duration of the scheme.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212420
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>The Government recognises that the Pharmaceutical Price Regulation Scheme (PPRS) payments that companies make under the 2014 scheme in respect of the United Kingdom need to be allocated to each of the devolved administrations in a fair way. Under the new arrangements introduced as part of the 2014 scheme, the apportionments will be agreed with the devolved administrations each year. The method for apportioning 2014-15 payments has not yet been finalised.</p><p> </p><p> </p><p> </p><p>It is a matter for the devolved health administrations to decide how to use the apportioned payments they receive from the PPRS.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:36:17 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101583

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make it his policy to use the Pharmaceutical Price Regulation Scheme to make the UK (a) a global leader in providing patients access to the most innovative appropriate medicines and (b) an attractive place for pharmaceutical companies to locate and invest.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212419
answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) supports the National Health Service to improve patient access to clinically and cost effective medicines in a number of ways:</p><p> </p><p> </p><p> </p><p>- by making medicines more affordable. The PPRS limits growth in the vast majority of spend on branded medicines with industry making payments for spend above the agreed limit;</p><p> </p><p> </p><p> </p><p>- by providing stability and predictability to the Government and the pharmaceutical industry thereby promoting a strong and profitable pharmaceutical industry which encourages innovation and the development of high value treatments; and</p><p> </p><p> </p><p> </p><p>- by a number of agreed measure to improve access to branded medicines commensurate with the outcomes they offer patients.</p><p> </p><p> </p><p> </p><p>Sales of new products are exempt from PPRS payments though still included in the overall limit on growth and the payments made by industry as a whole. This creates a strong in-built incentive in the scheme for companies to innovate.</p><p> </p><p><br> In respect of England, the anticipated PPRS payments for 2014-15 were passed on to NHS England through the Mandate and as such were included within commissioner allocations. In addition, an indicative budget for NHS England for 2015-16 was set on the basis of, amongst other things, the PPRS payment forecast available in 2014. <br> <br> In accordance with normal Government accounting rules and the agreed PPRS, there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients’ health and care. As part of this, following discussion with the Department, NHS England and the Association of the British Pharmaceutical Industry are now pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.</p><p> </p><p> </p><p> </p><p>More generally, the Government’s <em>Strategy for UK Life Sciences</em> sets out an ambitious long-term programme of action to improve the wider environment for pharmaceutical innovation and make the United Kingdom a world-leading place for life sciences investment. The Strategy has delivered £2 billion in industry and private sector investment in the United Kingdom since it was launched in December 2011.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212417 212418 question first answered 04/11/2014 17:36:41 answering member 4020 label Biography information for George Freeman previous answer version 25832 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper